Diagnostic performance of metagenomic next-generation sequencing for the detection of pathogens in bronchoalveolar lavage fluid in patients with pulmonary infections: Systematic review and meta-analysis

• Published in: International journal of infectious diseases Vol. 122; pp. 867 - 873
• Main Authors: Chen, Shenglin, Kang, Yutong, Li, Dan, Li, Zhenjun
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.09.2022; Elsevier
• Subjects: Bronchoalveolar lavage fluid; Diagnosis; Meta-analysis; Metagenomic next-generation sequencing; Pulmonary infection; OR; CI; BALF; Pulmonary infection; TB; Meta-analysis; RICU; CNKI; LRTI; Bronchoalveolar lavage fluid; Metagenomic next-generation sequencing; PI; Diagnosis; PCP; PCR; mNGS
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2022.07.054

•A meta-analysis of the accuracy of metagenomic next-generation sequencing (mNGS) for pulmonary infections (PIs).•Specimen type in patients with PIs is bronchoalveolar lavage fluid.•We discovered that mNGS is more sensitive in patients with severe PIs.•We identified the great potential of mNGS to diagnose PIs. Identifying pathogens in patients with pulmonary infection (PI) has always been a major challenge in medicine. Compared with sputum and throat swabs, bronchoalveolar lavage fluid (BALF) can better reflect the actual state of the lungs. However, there has not been a meta-analysis of the diagnostic efficacy of metagenomic next-generation sequencing (mNGS) in detecting pathogens in BALF from patients with PIs. Data sources were PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure. The pooled sensitivity and specificity were estimated using random-effects or fixed-effect models. Subgroup analysis was performed to reveal the effect of potential explanatory factors on the diagnostic performance measures. The pooled sensitivity was 78% (95% confidence interval [CI]: 67-87%; I2 = 92%) and the pooled specificity was 77% (95% CI: 64-94%; I2 = 74%) for mNGS. Subgroup analyses for the sensitivity of mNGS revealed that patients with PIs who were severely ill or immunocompromised significantly affected heterogeneity (P < 0.001). The positive detection rate of mNGS for pathogens in BALF of severely or immunocompromised pulmonary-infected patients was 92% (95% CI: 78-100%). mNGS has high diagnostic performance for BALF pathogens in patients with PIs, especially in critically ill or immunocompromised patients.